Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals Share Price Today

(NASDAQ: ARWR)

Arrowhead Pharmaceuticals share price is $19.9 & ₹1,723.50 as on 22 Feb 2025, 2.30 'hrs' IST

$19.9

-1.06

(-5.06%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Arrowhead Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Arrowhead Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Arrowhead Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Arrowhead Pharmaceuticals share price movements

  • Today's Low: $19.89
    Today's High: $21.25

    Day's Volatility :6.42%

  • 52 Weeks Low: $17.05
    52 Weeks High: $36.72

    52 Weeks Volatility :53.57%

Arrowhead Pharmaceuticals (ARWR) Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
5.91%
1.6%
0.0%
6 Months
-19.43%
-5.8%
0.0%
1 Year
-34.73%
-1.0%
0.0%
3 Years
-54.76%
15.2%
-11.4%

Arrowhead Pharmaceuticals (ARWR) Key Statistics

in dollars & INR

Previous Close
$20.96
Open
$21.2
Today's High
$21.25
Today's Low
$19.885
Market Capitalization
$2.5B
Today's Volume
$1.2M
52 Week High
$36.72
52 Week Low
$17.05
Revenue TTM
$2.5M
EBITDA
$-606.4M
Earnings Per Share (EPS)
$-5.15
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.1%
Return On Equity TTM
-565.33%

How to invest in Arrowhead Pharmaceuticals Stock (ARWR) from India?

It is very easy for Indian residents to invest directly in Arrowhead Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arrowhead Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arrowhead Pharmaceuticals or ARWR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arrowhead Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arrowhead Pharmaceuticals shares which would translate to 0.044 fractional shares of Arrowhead Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Arrowhead Pharmaceuticals, in just a few clicks!

Returns in Arrowhead Pharmaceuticals (ARWR) for Indian investors in Rupees

The Arrowhead Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrowhead Pharmaceuticals investment value today

Current value as on today

₹69,774

Returns

₹30,226

(-30.23%)

Returns from Arrowhead Pharmaceuticals Stock

₹34,733 (-34.73%)

Dollar Returns

₹4,507 (+4.51%)

Indian investors sentiment towards Arrowhead Pharmaceuticals (ARWR)

70%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Arrowhead Pharmaceuticals Stock from India on INDmoney has increased by 70% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arrowhead Pharmaceuticals

  • BlackRock Inc

    12.66%

  • Vanguard Group Inc

    9.74%

  • venBio Select Advisor LLC

    8.88%

  • State Street Corp

    5.08%

  • FMR Inc

    4.85%

  • Slate Path Capital LP

    4.18%

Analyst Recommendation on Arrowhead Pharmaceuticals

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
5
Sell
0
0
0

Analyst Forecast on Arrowhead Pharmaceuticals Stock (ARWR)

What analysts predicted

Upside of 130.08%

Target:

$45.79

Current:

$19.90

Insights on Arrowhead Pharmaceuticals Stock (Ticker Symbol: ARWR)

  • Price Movement

    In the last 3 months, ARWR stock has moved up by 7.3%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 16.09M → 2.5M (in $), with an average decrease of 53.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -170.53M → -173.08M (in $), with an average decrease of 1.5% per quarter
  • ARWR vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.0% return, outperforming this stock by 96.0%
  • ARWR vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 63.9% return, outperforming this stock by 118.4%
  • Price to Sales

    ForARWR every $1 of sales, investors are willing to pay $995.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Arrowhead Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Arrowhead Pharmaceuticals (ARWR) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc. logo
-1.73%
-19.43%
-34.73%
-54.76%
-44.81%
Biontech Se logo
0.22%
37.14%
28.33%
-20.32%
255.59%
Regeneron Pharmaceuticals, Inc. logo
2.28%
-41.61%
-29.21%
13.2%
52.94%
Vertex Pharmaceuticals Incorporated logo
9.09%
0.33%
11.71%
110.26%
108.69%
Alnylam Pharmaceuticals, Inc. logo
-9.45%
-6.89%
57.94%
61.67%
112.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrowhead Pharmaceuticals, Inc. logo
NA
NA
-1.32
-3.6
-5.65
-0.48
NA
0.42
Biontech Se logo
160.8
NA
0.04
-3.29
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
18.16
18.16
1.01
43.09
0.16
0.07
0.01
273.57
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.3
18.11
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.59
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrowhead Pharmaceuticals, Inc. logo
Buy
$2.5B
-44.81%
NA
0.0%
Biontech Se logo
Buy
$28.3B
255.59%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$76.1B
52.94%
18.16
31.07%
Vertex Pharmaceuticals Incorporated logo
Buy
$123.3B
108.69%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$32.5B
112.27%
NA
-12.37%

Arrowhead Pharmaceuticals Dividend announcements

  • Arrowhead Pharmaceuticals Earnings

    Arrowhead Pharmaceuticals’s price-to-earnings ratio stands at None

    Read More

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Organization
Arrowhead Pharmaceuticals
Employees
609
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Management People of Arrowhead Pharmaceuticals

NameTitle
Dr. Christopher R. Anzalone Ph.D.
Chairman, CEO & President
Mr. Kenneth A. Myszkowski CPA, CPA, MBA
Chief Financial Officer
Mr. Patrick O'Brien J.D., PharmD
COO, General Counsel & Secretary
Dr. James C. Hamilton M.D., MBA
Chief of Discovery & Translational Medicine
Dr. Mark M. Davis Ph.D.
Founder and Founder & Director of Insert Therapeutics Inc & Calando
Dr. Vincent Anzalone CFA
Head of Investor Relations & VP
Mr. Howard Lovy
Director of Communications
Dr. Bruce D. Given M.D.
Chief Medical Scientist
Dr. Mark Seefeld
Head of Toxicology & VP
Aaron Tan
Head of Tax

Important FAQs about investing in ARWR Stock from India :

What is Arrowhead Pharmaceuticals share price today?

Arrowhead Pharmaceuticals share price today stands at $19.90, Open: $21.20 ; Previous Close: $20.96 ; High: $21.25 ; Low: $19.89 ; 52 Week High: $36.72 ; 52 Week Low: $17.05.

The stock opens at $21.20, after a previous close of $20.96. The stock reached a daily high of $21.25 and a low of $19.89, with a 52-week high of $36.72 and a 52-week low of $17.05.

Can Indians buy Arrowhead Pharmaceuticals shares?

Yes, Indians can invest in the Arrowhead Pharmaceuticals (ARWR) from India.

With INDmoney, you can buy Arrowhead Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Arrowhead Pharmaceuticals at zero transaction cost.

How can I buy Arrowhead Pharmaceuticals shares from India?

It is very easy to buy Arrowhead Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arrowhead Pharmaceuticals (ARWR) be purchased?

Yes, you can buy fractional shares of Arrowhead Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Arrowhead Pharmaceuticals stocks?

To start investing in Arrowhead Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Arrowhead Pharmaceuticals Stock (ARWR)?

Today’s highest price of Arrowhead Pharmaceuticals (ARWR) is $21.25.

Today’s lowest price of Arrowhead Pharmaceuticals (ARWR) is $19.89.

What is today's market capitalisation of Arrowhead Pharmaceuticals?

Today's market capitalisation of Arrowhead Pharmaceuticals ARWR is 2.5B

What is the 52 Week High and Low Range of Arrowhead Pharmaceuticals Stock (ARWR)?

  • 52 Week High

    $36.72

  • 52 Week Low

    $17.05

What are the historical returns of Arrowhead Pharmaceuticals (ARWR)?

  • 1 Month Returns

    -1.73%

  • 3 Months Returns

    -19.43%

  • 1 Year Returns

    -34.73%

  • 5 Years Returns

    -44.81%

Who is the Chief Executive Officer (CEO) of Arrowhead Pharmaceuticals ?

Dr. Christopher R. Anzalone Ph.D. is the current Chief Executive Officer (CEO) of Arrowhead Pharmaceuticals.